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Isolated antibody to hepatitis B core is associated with
hepatitis C virus co-infection
Jilg et al. [1] have previously shown that subjects with antibody
only to hepatitis B core (anti-HBc alone) were more often co-
infected with hepatitis C (HCV) (49%) than were subjects
who also had antibodies to hepatitis B surface antigen (anti-
HBs) in addition to anti-HBc (10%, P< 0.001). Hofer et al.
[2] reported a high prevalence of the anti-HBc alone pattern in
human immunode¢ciency virus (HIV) co-infected subjects.
They found that this pattern was present in 195 (43%) of their
450 HIV and hepatitis B virus (HBV) co-infected subjects.
They detected HBV-DNA in 51 (89.5%) of 57 subjects tested,
and as many as 33 of those (57.9%) were also positive for anti-
bodies to HCV.The respective contribution of HCVand HIV
co-infection on the prevalence of the anti-HBc alone pattern
is still unknown.
We made a retrospective survey of all HBVand HCV mar-
kers simultaneously detected in our laboratory over a 50-
month period from January 1, 1994 to February 9, 1998. Sera
were taken from patients with elevated transaminases, hepati-
tis, liver cirrhosis or from asymptomatic subjects, mainly
intravenous drug users (Table1). Anti-HBc, anti-HBs, HBsAg
and anti-HCV were tested using the Cobas Core enzyme
immunoassay (Roche, Basel, Switzerland); their sensitivity
and speci¢city of all was above 99.5%. As none of 104 subjects
with isolated anti-HBc was shown to be HBV DNA-positive
by polymerase chain reaction (PCR) [3], we decided not to
assay DNA levels. Of 972 samples positive for anti-HBc, 199
(20%) were from a`nti-HBc alone' subjects. The a`nti-HBc
alone' pattern was found more frequently in HCVco-infected
(30%) subjects than in those negative for antibodies to HCV
(17%). Consequently, the HCV prevalence was signi¢cantly
higher in the a`nti-HBc alone' subjects than in those also posi-
tive for HBsAg or anti-HBs antibodies (PR 0.0005,Table1).
We also obtained similar results in 276 HIV-negative subjects,
where the prevalence of anti-HCVwas 44% in 73 a`nti-HBc
alone' subjects, as compared to 12.5% in eight with HBsAg
and 33% in195 with anti-HBs. In the 532 subjects also positive
for anti-HBs, the level of anti-HBs antibody was lower in
anti-HCV positives than in negatives; indeed, only 42% [56/
134] of HCV-positive subjects had anti-HBs levels above 100
IU/L as compared to 61% [241/398] of HCV-negatives (P<
0.001).
We were thus able to con¢rm an association between the
a`nti-HBc alone' status of HBV infection and HCVco-infec-
tion, and also in a population not infected by HIV. In carriers
of both anti-HBc and anti-HBs, we found lower levels of anti-
HBs in those co-infectedwithHCVthan in non-infected sub-
jects. These ¢ndings suggest that HCV infection might sup-
press antibody production or even viral replication, thus
leading to the persistent anti-HBc-positive state but negative
for anti-HBs andHBsAg.
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CORRESPONDENCE
Table 1 HCV prevalence according to HBV markers and indication of HBV-HCV serology in anti-HBc alone subjects
HBV markers Total (n972) aHCV-positives (n257) %
aHBs and aHBc-positive 532 134 25
HBsAg and aHBc-positive 241 46 19
aHBc alone 199 77 39a
Hepatic involvmentb 44 10 23
No evidence of liver diseasec 122 40 33
Intravenous drug users 33 27 82
aP R 0.0005 as compared to both other groups; belevated liver enzymes, clinical hepatitis, liver cirrhosis, jaundice, hepatic graft; cexcept
intravenous drug users.
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